Tag: Gilead Sciences Inc

Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio

The power of genetic testing: new screening methods are catching rare diseases before symptoms start

CAMP4 advances rare disease treatment for SYNGAP1 into human trials

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

New Medicaid work rules could cause patients to lose coverage, rare disease advocates warn

Drugmakers race to find a place in the next wave of obesity drugs

AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

Bristol Myers Squibb turns to China to develop new drugs in newest cross-continent collaboration

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion